Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2018

01-02-2018 | Original Article

Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis

Authors: Hidetatsu Outani, Yoshinori Imura, Takaaki Tanaka, Satoshi Takenaka, Kazuya Oshima, Kenichiro Hamada, Shigeki Kakunaga, Susumu Joyama, Norifumi Naka, Ikuo Kudawara, Takafumi Ueda, Nobuhito Araki, Hideki Yoshikawa

Published in: International Journal of Clinical Oncology | Issue 1/2018

Login to get access

Abstract

Purpose

An epithelioid sarcoma is a rare histological subtype of a soft tissue sarcoma with a high local recurrence rate, which frequently shows lymph node metastasis. However, because of the rarity of this tumor, the impact of nodal metastasis and its appropriate management remain unclear. The present study investigated the clinical outcomes of patients with epithelioid sarcomas, with a focus on lymph node metastasis.

Methods

We retrospectively evaluated the clinical outcomes of 27 patients with epithelioid sarcomas treated between 1985 and 2015. The log-rank test was used to assess the prognostic variables.

Results

The overall local recurrence rate was 33%, and the estimated overall 5-year survival rate was 62%. Hand and foot locations were associated with favorable overall survival. During the follow-up period, new nodal metastasis was noted in 14 patients (52%). The incidence of local recurrence was higher in patients with new nodal metastasis than in patients who did not develop nodal metastasis. The development of new nodal metastasis had a tendency to worsen survival; however, this association was not statistically significant. Lymphadenectomy did not affect overall survival.

Conclusions

Peripheral tumor location is associated with a better prognosis. The development of new nodal metastasis tends to be associated with poor prognosis; however, among patients with nodal metastasis, resection of the metastatic lesions has a low impact on survival.

Literature
  1. Goldblum JR, Flope AL, Weiss SW (2013) Malignant soft tissue tumors of uncertain type. Enzinger and Weiss’s soft tissue tumors, 6th edn. Elsevier, Philadelphia, pp 1086–1098
  2. Enzinger FM (1970) Epithelioid sarcoma; a sarcoma simulating a granuloma or a carcinoma. Cancer 26:1029–1041View ArticlePubMed
  3. Prat J, Woodruff JM, Marcove RC (1978) Epithelioid sarcoma: an analysis of 22 cases indicating the prognostic significance of vascular invasion and regional lymph node metastasis. Cancer 41:1472–1487View ArticlePubMed
  4. Jawad MU, Extein J, Min ES et al (2009) Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res 467:2939–2948View ArticlePubMedPubMed Central
  5. de Visscher SA, van Ginkel RJ, Wobbes T et al (2006) Epithelioid sarcoma: still an only surgically curable disease. Cancer 107:606–612View ArticlePubMed
  6. Wolf PS, Flum DR, Tanas MR et al (2008) Epithelioid sarcoma: the University of Washington experience. Am J Surg 196:407–412View ArticlePubMed
  7. Trojani M, Contesso G, Coindre JM et al (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37–42View ArticlePubMed
  8. Spillane AJ, Thomas JM, Fisher C (2000) Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol 7:218–225View ArticlePubMed
  9. Callister MD, Ballo MT, Pisters PW et al (2001) Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 51:384–391View ArticlePubMed
  10. Livi L, Shah N, Paiar F et al (2003) Treatment of epithelioid sarcoma at the royal marsden hospital. Sarcoma 7:149–152View ArticlePubMedPubMed Central
  11. Baratti D, Pennacchioli E, Casali PG et al (2007) Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 14:3542–3551View ArticlePubMed
  12. Rekhi B, Gorad BD, Chinoy RF (2008) Clinicopathological features with outcomes of a series of conventional and proximal-type epithelioid sarcomas, diagnosed over a period of 10 years at a tertiary cancer hospital in India. Virchows Arch 453:141–153View ArticlePubMed
  13. Gasparini P, Facchinetti F, Boeri M et al (2011) Prognostic determinants in epithelioid sarcoma. Eur J Cancer 47:287–295View ArticlePubMed
  14. Guzzetta AA, Montgomery EA, Lyu H et al (2012) Epithelioid sarcoma: one institution’s experience with a rare sarcoma. J Surg Res 177:116–122View ArticlePubMedPubMed Central
  15. Levy A, Le Pechoux C, Terrier P et al (2014) Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment. Ann Surg Oncol 21:269–276View ArticlePubMed
  16. Asano N, Yoshida A, Ogura K et al (2015) Prognostic value of relevant clinicopathologic variables in epithelioid sarcoma: a multi-institutional retrospective study of 44 patients. Ann Surg Oncol 22:2624–2632View ArticlePubMedPubMed Central
  17. Chase DR, Enzinger FM (1985) Epithelioid sarcoma: diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 9:241–263View ArticlePubMed
  18. Jones RL, Constantinidou A, Olmos D et al (2012) Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol 35:351–357View ArticlePubMed
  19. Nakamura T, Matsumine A, Kawai A et al (2016) The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122:1408–1416View ArticlePubMedPubMed Central
  20. Casanova M, Ferrari A, Colloni P et al (2006) Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer 1068:708–717View Article
  21. Daigeler A, Kuhnen C, Moritz R et al (2009) Lymph node metastases in soft tissue sarcoma: a single center analysis of 1597 patients. Langenbecks Arch Surg 394:321–329View ArticlePubMed
  22. Fong Y, Colit DG, Woodruff JM et al (1993) Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 217:72–77View ArticlePubMedPubMed Central
  23. Al-Refaie WB, Andtbacka RH, Ensor J et al (2008) Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. Cancer 112:1821–1826View ArticlePubMed
  24. Sawamura C, Matsumoto S, Shimoji T et al (2013) Lymphadenectomy and histologic subtype affect overall survival of soft tissue sarcoma patients with nodal metastases. Clin Orthop Relat Res 471:926–931View ArticlePubMed
  25. Herr MJ, Harmsen WS, Amadio PC et al (2005) Epithelioid sarcoma of the hand. Clin Orthod Relat Res 431:193–200View Article
Metadata
Title
Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis
Authors
Hidetatsu Outani
Yoshinori Imura
Takaaki Tanaka
Satoshi Takenaka
Kazuya Oshima
Kenichiro Hamada
Shigeki Kakunaga
Susumu Joyama
Norifumi Naka
Ikuo Kudawara
Takafumi Ueda
Nobuhito Araki
Hideki Yoshikawa
Publication date
01-02-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1179-x

Other articles of this Issue 1/2018

International Journal of Clinical Oncology 1/2018 Go to the issue

Original Article

Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan

Original Article

Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review

Original Article

Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up

Original Article

A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma

Original Article

The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan

Original Article

Radiation therapy versus surgery for patients with cervical squamous cell carcinoma who have undergone neoadjuvant chemotherapy revisited
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits